Winette T. A. Van Der Graaf

Winette T. A. Van Der Graaf's AcademicInfluence.com Rankings

Philosophy

#7448

World Rank

#10665

Historical Rank

Logic

#4497

World Rank

#5802

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Winette T. A. Van Der Graaf's Degrees

PhD Biomedical Sciences University of Amsterdam
Doctorate Medicine University of Amsterdam

Why Is Winette T. A. Van Der Graaf Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Winette T. A. Van Der Graaf's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. (2014) (808)
Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (624)
Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. (2000) (465)
The impact of parental cancer on children and the family: a review of the literature. (2004) (328)
Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility (2002) (280)
The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. (2004) (280)
Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. (2006) (278)
Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. (2000) (254)
An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG) (2017) (250)
Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (244)
Mycobacterium ulcerans disease. (2005) (242)
Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (230)
Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis (2012) (221)
Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (216)
Spinal Extradural Metastasis: Review of Current Treatment Options (2008) (212)
Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2021) (206)
Monitoring and Predicting Response to Therapy with 18F-FDG PET in Colorectal Cancer: A Systematic Review (2009) (204)
Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases. (2007) (204)
Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. (2001) (199)
Complete in vivo reversal of P‐glycoprotein pump function in the blood‐brain barrier visualized with positron emission tomography (1998) (195)
Starting an adolescent and young adult program: some success stories and some obstacles to overcome. (2010) (193)
The blood-brain barrier and oncology: new insights into function and modulation. (2000) (185)
Low-penetrance genes and their involvement in colorectal cancer susceptibility. (2002) (185)
Management of sporadic desmoid-type fibromatosis: a European consensus approach based on patients' and professionals' expertise - a sarcoma patients EuroNet and European Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group initiative. (2015) (184)
Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. (2005) (181)
The insulin-like growth factor 1 receptor in cancer: old focus, new future. (2007) (177)
Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. (2008) (176)
Visualization of multidrug resistance in vivo (1999) (172)
Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. (2009) (164)
Risk factors for Buruli ulcer disease (Mycobacterium ulcerans Infection): results from a case-control study in Ghana. (2005) (164)
The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours. (2004) (164)
Beliefs and attitudes toward Buruli ulcer in Ghana. (2002) (163)
An oncological view on the blood-testis barrier. (2002) (159)
Emotional and behavioural functioning of children of a parent diagnosed with cancer: a cross‐informant perspective (2005) (154)
Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. (2011) (154)
Histopathologic Features of Mycobacterium ulcerans Infection (2003) (150)
99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. (1998) (148)
Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (147)
Detection of anthracycline-induced cardiotoxicity. (1999) (145)
111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. (2007) (144)
The insulin‐like growth factor system and sarcomas (2009) (143)
A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. (1999) (142)
BREATH: Web-Based Self-Management for Psychological Adjustment After Primary Breast Cancer--Results of a Multicenter Randomized Controlled Trial. (2015) (135)
Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. (2014) (134)
Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients (2011) (133)
Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (131)
Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET (2004) (129)
Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis (2017) (120)
Stress response symptoms in adolescent and young adult children of parents diagnosed with cancer. (2005) (117)
Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis--an EORTC STBSG and ROG study (EORTC 62991-22998). (2013) (116)
Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables (1999) (114)
Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications. (2012) (114)
Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Tr (2017) (110)
The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands (2007) (110)
The quality of communication between parents and adolescent children in the case of parental cancer. (2005) (109)
Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity. (2016) (107)
Long-term chemotherapy-related cardiovascular morbidity. (2000) (104)
A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients (2012) (104)
Solitary fibrous tumor – clinicopathologic, immunohistochemical and molecular analysis of 28 cases (2014) (103)
Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study. (2005) (103)
Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era (2001) (102)
Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET. (1996) (102)
Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. (1994) (96)
Mycobacterium ulcerans infection in Ashanti region, Ghana. (1989) (96)
Pretargeted Immuno–Positron Emission Tomography Imaging of Carcinoembryonic Antigen–Expressing Tumors with a Bispecific Antibody and a 68Ga- and 18F-Labeled Hapten Peptide in Mice with Human Tumor Xenografts (2010) (96)
ImmunoSPECT and ImmunoPET of IGF-1R Expression with the Radiolabeled Antibody R1507 in a Triple-Negative Breast Cancer Model (2010) (95)
Psychosocial Consequences for Children of a Parent With Cancer: A Pilot Study (2003) (91)
Susceptibility to development of Mycobacterium ulcerans disease: review of possible risk factors (2001) (91)
Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. (2017) (90)
Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072. (2014) (89)
Soft tissue sarcomas in adolescents and young adults: a comparison with their paediatric and adult counterparts. (2017) (88)
Cancer in adolescents and young adults (15–29 years): A population-based study in the Netherlands 1989–2009 (2012) (88)
Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. (2005) (88)
Corrections to "Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up". (2018) (86)
Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2021) (85)
Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy (2002) (83)
Bone sarcomas: ESMO-EURACAN-GENTURIS-ERNPaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. (2021) (83)
First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials. (2014) (82)
Epidemiological aspects of soft tissue sarcomas (STS)--consequences for the design of clinical STS trials. (1999) (82)
Teenagers and young adults with cancer in Europe: from national programmes to a European integrated coordinated project. (2016) (81)
First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors (2016) (81)
Androgen deprivation therapy for androgen receptor‐positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands (2017) (77)
Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review. (2011) (75)
Age as an independent prognostic factor for survival of localised synovial sarcoma patients (2015) (75)
Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with 18F-Labeled Affibody Molecule ZHER2:2395 in a Mouse Model for Ovarian Cancer (2012) (73)
Family‐oriented multilevel study on the psychological functioning of adolescent children having a mother with cancer (2011) (72)
Variability in axillary lymph node dissection for breast cancer (2004) (71)
Complications of venous access ports in 132 patients with disseminated testicular cancer treated with polychemotherapy. (1996) (71)
Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (71)
Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network (2020) (70)
Clinicopathologic assessment of postradiation sarcomas: KIT as a potential treatment target. (2003) (67)
Surgical management of rectal gastrointestinal stromal tumors (2013) (66)
Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results (2013) (66)
Familial testicular cancer in a single-centre population. (1999) (66)
The reverse side of the victory: Flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases (2009) (64)
Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer. (1995) (63)
Post-Traumatic Growth and Resilience in Adolescent and Young Adult Cancer Patients: An Overview. (2017) (62)
Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib. (2013) (61)
Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4. (1996) (60)
Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE) (2021) (60)
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’ (2017) (60)
The EORTC QLQ-C30 Summary Score as Prognostic Factor for Survival of Patients with Cancer in the "Real-World": Results from the Population-Based PROFILES Registry. (2020) (60)
A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trial. (2015) (59)
Soft tissue sarcoma of the extremities. A multimodality diagnostic and therapeutic approach. (1998) (59)
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’ (2017) (58)
Phase I study of transforming growth factor-beta3 mouthwashes for prevention of chemotherapy-induced mucositis. (1999) (57)
Impact of Concomitant Administration of Gastric Acid–Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials (2019) (57)
EORTC-GCG process quality indicators for ovarian cancer surgery. (2009) (57)
Family functioning and adolescents' emotional and behavioral problems: when a parent has cancer. (2007) (56)
Systemic Treatment for Adults with Synovial Sarcoma (2018) (55)
Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG)† (2018) (55)
Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib (2016) (54)
Parental cancer (2006) (54)
Theranostic applications of antibodies in oncology (2014) (54)
Ultra‐rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities (2021) (53)
Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity. (2008) (53)
The HLA class III subregion is responsible for an increased breast cancer risk. (2003) (53)
Buruli ulcer: differences in treatment outcome between two centres in Ghana. (2003) (52)
The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma (2014) (51)
Assessment of functional limitations caused by Mycobacterium ulcerans infection: towards a Buruli Ulcer Functional Limitation Score (2003) (51)
Analysis of an IS2404-Based Nested PCR for Diagnosis of Buruli Ulcer Disease in Regions of Ghana Where the Disease Is Endemic (2003) (51)
Quality of life of parents with children living at home: when one parent has cancer (2007) (51)
Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer. (1995) (50)
Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine. (2006) (50)
111In-Bevacizumab Imaging of Renal Cell Cancer and Evaluation of Neoadjuvant Treatment with the Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib (2010) (50)
Role of Endogenous Vascular Endothelial Growth Factor in Endothelium-Dependent Vasodilation in Humans (2013) (48)
Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent. (2017) (48)
Pretargeted 177Lu Radioimmunotherapy of Carcinoembryonic Antigen–Expressing Human Colonic Tumors in Mice (2010) (47)
Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults (2016) (47)
Corrections to "Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up". (2018) (47)
Next generation sequencing in synovial sarcoma reveals novel gene mutations (2015) (46)
Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience (2014) (46)
Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072. (2016) (45)
3′-Deoxy-3′-18F-Fluorothymidine PET–Derived Proliferative Volume Predicts Overall Survival in High-Grade Glioma Patients (2012) (45)
Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose (2019) (45)
Isolated Limb Perfusion with Tumor Necrosis Factor Alpha and Melphalan for Locally Advanced Soft Tissue Sarcoma: Three Time Periods at Risk for Amputation (2007) (44)
Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (43)
A nationwide cohort study on treatment and survival in patients with malignant peripheral nerve sheath tumours. (2019) (43)
Predicting IGF-1R Therapy Response in Bone Sarcomas: Immuno-SPECT Imaging with Radiolabeled R1507 (2011) (43)
Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma (2019) (43)
Metastatic potential of an aneurysmal bone cyst (2009) (43)
Metastasis in Soft Tissue Sarcomas: Prognostic Criteria and Treatment Perspectives (2004) (42)
Fever and neutropenia in cancer patients: the diagnostic role of cytokines in risk assessment strategies. (2002) (42)
Colorectal cancer and the CHEK2 1100delC mutation (2005) (41)
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study. (2016) (40)
Multidrug resistance proteins in rhabdomyosarcomas (2003) (40)
Cognitive behavioral therapy or graded exercise therapy compared with usual care for severe fatigue in patients with advanced cancer during treatment: a randomized controlled trial. (2020) (40)
Clinicopathological characteristics and outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed (mammary analogue) secretory carcinoma of salivary glands. (2018) (40)
Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study (2011) (40)
Distribution of Buruli ulcer lesions over body surface area in a large case series in Ghana: uncovering clues for mode of transmission. (2005) (39)
A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2. (1993) (39)
Pigmented villonodular synovitis: current concepts about diagnosis and management. (2013) (39)
Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group (2011) (39)
Routine chest X-rays have no additional value in the detection of relapse during routine follow-up of patients treated with chemotherapy for disseminated non-seminomatous testicular cancer. (2002) (38)
Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer (2010) (38)
Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: current hurdles and future perspectives. (2014) (38)
Adolescents' emotional reactions to parental cancer: effect on emotional and behavioral problems. (2011) (38)
Pazopanib, a promising option for the treatment of aggressive fibromatosis (2017) (38)
A new conservative approach to extravasation of anthracyclines with dimethylsulfoxide and dexrazoxane. (2001) (38)
Routine radiography does not have a role in the diagnostic evaluation of ambulatory adult febrile neutropenic cancer patients. (2003) (38)
Tailoring therapy in colorectal cancer by PET-CT. (2009) (38)
Stress response symptoms in adolescents during the first year after a parent’s cancer diagnosis (2010) (38)
Routine bone scintigraphy in primary staging of soft tissue sarcoma (2000) (37)
ATR Is a Therapeutic Target in Synovial Sarcoma. (2017) (37)
Historical, current and future aspects of osteosarcoma treatment. (1998) (37)
A new, simple and objective prognostic score for phase I cancer patients. (2011) (37)
Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile? (2012) (37)
Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials. (2015) (37)
PALETTE: A randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy-An EORTC STBSG Global Network Study (EORTC 62072). (2011) (37)
Temsirolimus for metastatic desmoplastic small round cell tumor (2010) (37)
Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma (2016) (36)
Systemic treatment in adult uterine sarcomas. (2018) (36)
The therapeutic challenge of a nonresectable solitary fibrous tumor in a hypoglycemic patient (2006) (36)
Epigenetic targeting in pancreatic cancer. (2014) (36)
A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment (2015) (36)
A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands (2018) (36)
Adolescent and young adult (AYA) lymphoma survivors report lower health-related quality of life compared to a normative population: results from the PROFILES registry (2017) (36)
Adherence to Guidelines for Adult (Non-GIST) Soft Tissue Sarcoma in the Netherlands: A Plea for Dedicated Sarcoma Centers (2017) (36)
Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: A Nonrandomized Controlled Trial. (2020) (35)
Empowerment in adolescents and young adults with cancer: Relationship with health‐related quality of life (2017) (35)
Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice. (2013) (35)
Prevalence and correlates of high fear of cancer recurrence in late adolescents and young adults consulting a specialist adolescent and young adult (AYA) cancer service (2017) (35)
Age as prognostic factor in patients with osteosarcoma. (2011) (35)
In vivo measurement of [11C]verapamil kinetics in human tissues (2001) (34)
Development of a questionnaire assessing Buruli ulcer-induced functional limitation. (2004) (34)
Anti-angiogenic therapy, a new player in the field of sarcoma treatment. (2014) (34)
Towards an evidence-based model of fear of cancer recurrence for breast cancer survivors (2016) (34)
Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts (2021) (34)
Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial. (2011) (34)
Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma. (2016) (33)
Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor (2019) (33)
Intensive chemotherapy with autologous bone marrow transfusion as primary treatment in women with breast cancer and more than five involved axillary lymph nodes. (1994) (33)
The sarcoma diagnostic interval: a systematic review on length, contributing factors and patient outcomes (2020) (33)
Outcome of Primary Desmoid Tumors at All Anatomic Locations Initially Managed with Active Surveillance (2019) (33)
Pheochromocytoma and gastrointestinal stromal tumors in patients with neurofibromatosis type I. (2013) (32)
The value of high-dose methotrexate-based neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone. (1996) (32)
Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial (2020) (32)
Expression of P‐glycoprotein, multidrug resistance‐associated protein 1, and lung resistance‐related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor‐α and melphalan (2001) (32)
Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients (2016) (32)
Evaluation of long term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniques (2002) (32)
Adolescent and Young Adult (AYA) Cancer Survivorship Practices: An Overview (2021) (31)
Absence of progression, not extent of tumour shrinkage, defines prognosis in soft-tissue sarcoma - An analysis of the EORTC 62012 study of the EORTC STBSG. (2016) (31)
Prognostic value of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 blood levels in breast cancer. (2013) (30)
Incidence, Survival, and Mortality Trends of Cancers Diagnosed in Adolescents and Young Adults (15–39 Years): A Population-Based Study in The Netherlands 1990–2016 (2020) (30)
Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent (2017) (30)
Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxantrone, doxorubicin, and vincristine in non-P-glycoprotein human small cell lung cancer cell lines. (1994) (30)
Doxorubicin potentiates TRAIL cytotoxicity and apoptosis and can overcome TRAIL-resistance in rhabdomyosarcoma cells. (2004) (30)
Optimization of IGF-1R SPECT/CT imaging using 111In-labeled F(ab')2 and Fab fragments of the monoclonal antibody R1507. (2012) (30)
Modulation of death receptor pathways in oncology. (2003) (30)
Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG) (2018) (30)
Reliability and validity of the Buruli ulcer functional limitation score questionnaire. (2005) (30)
Expression of multidrug resistance proteins, P-gp, MRP1 and LRP, in soft tissue sarcomas analysed according to their histological type and grade. (2003) (30)
Building the bridge between rhabdomyosarcoma in children, adolescents and young adults: the road ahead. (2012) (29)
Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients. (2017) (29)
Synovial sarcoma diagnosis and management in the era of targeted therapies (2015) (29)
Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method (2012) (29)
The EORTC QLQ‐C30 Summary Score as Prognostic Factor for Survival of Patients with Cancer in the “Real‐World”: Results from the Population‐Based PROFILES Registry (2019) (29)
Upregulation of IGF-1R Expression during Neoadjuvant Therapy Predicts Poor Outcome in Breast Cancer Patients (2015) (29)
Fear of progression in patients with gastrointestinal stromal tumors (GIST): Is extended lifetime related to the Sword of Damocles? (2015) (29)
Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes. (2017) (28)
Prevalence and impact of severe fatigue in adolescent and young adult cancer patients in comparison with population-based controls (2017) (28)
Age-related sarcoma patient experience: results from a national survey in England (2018) (28)
The impact of age on outcome of embryonal and alveolar rhabdomyosarcoma patients. A multicenter study. (2012) (28)
Targeted Therapy–based Combination Treatment in Rhabdomyosarcoma (2018) (27)
Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancer. (1997) (27)
Cardiotoxicity in advanced non-small cell lung cancer patients treated with platinum and non-platinum based combinations as first-line treatment. (2004) (26)
Decision-making process in patients before entering phase III cancer clinical trials: a pilot study. (1999) (26)
A single digital droplet PCR assay to detect multiple KIT exon 11 mutations in tumor and plasma from patients with gastrointestinal stromal tumors (2018) (26)
In vitro and in vivo modulation of multi‐drug resistance with amiodarone (1991) (26)
Psychosocial challenges and health-related quality of life of adolescents and young adults with hematologic malignancies. (2018) (26)
Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide. (1997) (26)
A Specific Distress Cutoff Score Shortly After Breast Cancer Diagnosis (2017) (26)
Parent‐child communication patterns during the first year after a parent's cancer diagnosis (2009) (26)
Prevalence, Impact, and Correlates of Severe Fatigue in Patients With Gastrointestinal Stromal Tumors. (2016) (26)
DNA Methylation Profiling Identifies Distinct Clusters in Angiosarcomas (2019) (26)
European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy. (2018) (26)
Feasibility and impact of a physical exercise program in patients with advanced cancer: a pilot study. (2014) (26)
Immunoglobulin M Antibody Responses to Mycobacterium ulcerans Allow Discrimination between Cases of Active Buruli Ulcer Disease and Matched Family Controls in Areas Where the Disease Is Endemic (2004) (25)
Angiogenesis inhibition in non-GIST soft tissue sarcomas. (2008) (25)
Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response (2018) (25)
Treatment of breast cancer cells by IGF1R tyrosine kinase inhibitor combined with conventional systemic drugs. (2012) (25)
Desmoid fibromatosis through the patients’ eyes: time to change the focus and organisation of care? (2018) (24)
Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study (2017) (24)
A prospective analysis on fatigue and experienced burden in informal caregivers of cancer patients during cancer treatment in the palliative phase (2015) (24)
Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era (2018) (24)
Insulin-like growth factors and insulin-like growth factor-binding proteins in relation to disease status and incidence of hypoglycaemia in patients with a gastrointestinal stromal tumour. (2009) (24)
A study of motivations and expectations of patients seen in phase 1 oncology clinics (2016) (24)
Online support community for adolescents and young adults (AYAs) with cancer: user statistics, evaluation, and content analysis (2018) (23)
Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B. (1999) (23)
Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial (2015) (23)
Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib (2017) (23)
Irradiation of rat brain reduces P-glycoprotein expression and function (2007) (23)
New Systemic Therapy Options for Advanced Sarcomas (2012) (23)
Clinical applications of positron emission tomography in sarcoma management (2011) (23)
Factors influencing haematological recovery following high-dose chemotherapy and peripheral stem-cell transplantation for haematological malignancies; 1-year analysis. (2004) (23)
Severe Fatigue During the Palliative Treatment Phase of Cancer: An Exploratory Study (2014) (23)
Expression of multidrug resistance-associated proteins in rhabdomyosarcomas before and after chemotherapy: the relationship between lung resistance-related protein (LRP) and differentiation. (2003) (22)
Toxicity and efficacy of accelerated radiotherapy with concurrent weekly cisplatin for locally advanced head and neck carcinoma (2016) (22)
Targeting angiosarcomas of the soft tissues: A challenging effort in a heterogeneous and rare disease. (2019) (22)
Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials. (2018) (22)
Impaired endothelium-dependent vasodilation does not initiate the development of sunitinib-associated hypertension (2015) (22)
Temperament as a predictor of internalising and externalising problems in adolescent children of parents diagnosed with cancer (2006) (21)
Use of natriuretic peptides for detecting cardiac dysfunction in long-term disease-free breast cancer survivors. (2005) (21)
Relevance of high-dose chemotherapy in solid tumours. (2005) (21)
Age‐related differences in health‐related quality of life among thyroid cancer survivors compared with a normative sample: Results from the PROFILES Registry (2018) (21)
No association between two MLH3 variants (S845G and P844L)and colorectal cancer risk. (2004) (21)
Non-islet cell tumour hypoglycaemia in a patient with a gastrointestinal stromal tumour (2005) (21)
Circulating apoptotic proteins are increased in long-term disease-free breast cancer survivors (2006) (21)
Pharmacokinetics of sunitinib in an obese patient with a GIST. (2008) (20)
Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients (2016) (20)
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'. (2019) (20)
Fatigue and its associated psychosocial factors in cancer patients on active palliative treatment measured over time (2015) (20)
The Relation Between Histological, Tumor-Biological and Clinical Parameters in Deep and Superficial Leiomyosarcoma and Leiomyoma (2002) (20)
Early Evaluation of Response Using 18F-FDG PET Influences Management in Gastrointestinal Stromal Tumor Patients Treated with Neoadjuvant Imatinib (2017) (20)
A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer (2010) (20)
Degree of nephrotoxicity after intermediate‐ or high‐dose cisplatin‐based chemoradiotherapy in patients with locally advanced head and neck cancer (2016) (20)
Diffusion Tensor Imaging and Chemical Shift Imaging Assessment of Heterogeneity in Low Grade Glioma Under Temozolomide Chemotherapy (2007) (20)
Patients’ Preferences for Information About the Benefits and Risks of Second-Line Palliative Chemotherapy and Their Oncologist’s Awareness of These Preferences (2015) (19)
Fatigue in Advanced Cancer Patients: Congruence Between Patients and Their Informal Caregivers About Patients' Fatigue Severity During Cancer Treatment With Palliative Intent and Predictors of Agreement. (2016) (19)
Skin ulcers misdiagnosed as pyoderma gangrenosum. (2003) (19)
Cancer in adolescents and young adults in north Netherlands (1989-2003): increased incidence, stable survival and high incidence of second primary tumours. (2009) (19)
Pazopanib exposure decreases as a result of an ifosfamide-dependent drug–drug interaction: results of a phase I study (2013) (19)
Elderly patients with gastrointestinal stromal tumour (GIST) receive less treatment irrespective of performance score or comorbidity - A retrospective multicentre study in a large cohort of GIST patients. (2017) (19)
The dilemma of the strive for apoptosis in oncology: mind the heart. (2005) (19)
The diagnostic hurdle of an elderly male with bone pain: how 18F-FDG-PET led to diagnosis of a leiomyosarcoma of the adrenal gland. (2009) (19)
A new in vitro assay for quantitation of chemotherapy-induced mucositis. (1997) (18)
Imaging of HIV-associated Kaposi sarcoma; F-18-FDG-PET/CT and In-111-bevacizumabscintigraphy. (2010) (18)
Prognostic Factors in a Large Nationwide Cohort of Histologically Confirmed Primary and Secondary Angiosarcomas (2019) (18)
PNU-145156E, a novel angiogenesis inhibitor, in patients with solid tumors: a phase I and pharmacokinetic study. (2001) (17)
Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma (2018) (17)
Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours (2010) (16)
Caregivers’ burden and fatigue during and after patients’ treatment with concomitant chemoradiotherapy for locally advanced head and neck cancer: a prospective, observational pilot study (2019) (16)
'Big'-insulin-like growth factor-II signaling is an autocrine survival pathway in gastrointestinal stromal tumors. (2012) (16)
Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072. (2014) (16)
Nuclear medicine imaging of infection in cancer patients (with emphasis on FDG-PET). (2011) (16)
No increased susceptibility to breast cancer from combined CHEK2 1100delC genotype and the HLA class III region risk factors. (2005) (16)
Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy. (2016) (16)
Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature (2021) (16)
Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma. (1994) (15)
Psychological impact of lymphoma on adolescents and young adults: not a matter of black or white (2016) (15)
Abundant Fas expression by gastrointestinal stromal tumours may serve as a therapeutic target for MegaFasL (2008) (15)
Adolescents and Young Adults Living With an Uncertain or Poor Cancer Prognosis: The "New" Lost Tribe. (2021) (15)
Buruli ulcer and schistosomiasis: no association found. (2004) (15)
Identification and assessment of health-related quality of life issues in patients with sporadic desmoid-type fibromatosis: a literature review and focus group study (2018) (15)
Patient and diagnostic intervals of survivors of sarcoma: Results from the SURVSARC study (2020) (15)
The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24–25, 2015. Workshop Report (2016) (14)
The Role of Oral Mucositis on the Systemic Inflammation Parameter IL-8 in Febrile Neutropenic Cancer Patients (2006) (14)
Unravelling the heterogeneity of soft tissue and bone sarcoma patients’ health-related quality of life: a systematic literature review with focus on tumour location (2020) (14)
Embryonal and Alveolar Rhabdomyosarcoma in Adults: Real-Life Data From a Tertiary Sarcoma Centre. (2019) (13)
Tumor-receptor imaging in breast cancer: a tool for patient selection and response monitoring. (2013) (13)
Prophylactic antibiotics reduce hospitalisations and cost in locally advanced head and neck cancer patients treated with chemoradiotherapy: A randomised phase 2 study. (2019) (13)
Radionuclide imaging of drug delivery for patient selection in targeted therapy (2014) (13)
Testicular carcinoma and HLA Class II genes (2002) (13)
Unraveling the Heterogeneity of Sarcoma Survivors’ Health-Related Quality of Life Regarding Primary Sarcoma Location: Results from the SURVSARC Study (2020) (13)
99mTc-Sestamibi scanning with SDZ PSC 833 as a functional detection method for resistance modulation in patients with solid tumours. (1999) (13)
Imaging Response Evaluation after Neoadjuvant Treatment in Soft Tissue Sarcomas: Where Do We Stand? (2021) (13)
Cellular Radiosensitivity of Soft Tissue Sarcoma (2021) (13)
The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials. (2018) (13)
Evaluation of S9788 as a potential modulator of drug resistance against human tumour sublines expressing differing resistance mechanisms In Vitro (1993) (12)
Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo (2020) (12)
Measurement of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 after delayed separation of whole blood samples. (2008) (12)
Aggressive fibromatosis in the head and neck region: Benign tumor with often mutilating effects (2013) (12)
Outcome of Nonsurgical Management of Extra-Abdominal, Trunk, and Abdominal Wall Desmoid-Type Fibromatosis: A Population-Based Study in the Netherlands (2018) (12)
Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours - Results from daily clinical practice. (2020) (12)
Not as Stable as We Think: A Descriptive Study of 12 Monthly Assessments of Fear of Cancer Recurrence Among Curatively-Treated Breast Cancer Survivors 0–5 Years After Surgery (2020) (12)
Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study. (1997) (12)
Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials (2019) (12)
Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin (2016) (12)
The relationship between sunitinib exposure and both efficacy and toxicity in real‐world patients with renal cell carcinoma and gastrointestinal stromal tumour (2020) (12)
The strength of small: improved targeting of insulin-like growth factor-1 receptor (IGF-1R) with F(ab')₂-R1507 fragments in Ewing sarcomas. (2013) (12)
Collaboration and Networking. (2016) (12)
Neoadjuvant Systemic Treatment of Primary Angiosarcoma (2020) (12)
Quantitative Immuno-SPECT Monitoring of Pretargeted Radioimmunotherapy with a Bispecific Antibody in an Intraperitoneal Nude Mouse Model of Human Colon Cancer (2012) (12)
Gastrointestinal Stromal Tumours (GIST) in Young Adult (18–40 Years) Patients: A Report from the Dutch GIST Registry (2020) (12)
The effect of surgery in tenosynovial giant cell tumours as measured by patient-reported outcomes on quality of life and joint function. (2019) (11)
Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness (2018) (11)
Predictive factors for toxicity and survival of second-line sunitinib in advanced gastrointestinal stromal tumours (GIST) (2016) (11)
Neo-adjuvant chemotherapy with carboplatin, 4-epiadriamycin and teniposide (CET) in locally advanced cancer of the cardia and the lower oesophagus: a phase II study. (1995) (11)
Tumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapy (2015) (11)
Multidrug resistance proteins in primary and metastatic soft-tissue sarcomas: down-regulation of P-glycoprotein during metastatic progression. (2004) (11)
Phase II study of intraperitoneal cisplatin plus systemic etoposide as second-line treatment in patients with small volume residual ovarian cancer. (1995) (11)
ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe. (2022) (10)
Seizures in a patient with disseminated testicular cancer due to cisplatin-induced hypomagnesaemia. (2000) (10)
Promising novel therapeutic approaches in the management of gastrointestinal stromal tumors. (2017) (10)
Abscopal effect of radiotherapy in a patient with metastatic diffuse-type giant cell tumor (2016) (10)
Experiences of Parents and General Practitioners with End-of-Life Care in Adolescents and Young Adults with Cancer. (2016) (10)
Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment (2022) (10)
Diagnosed with a Rare Cancer: Experiences of Adult Sarcoma Survivors with the Healthcare System—Results from the SURVSARC Study (2021) (10)
The fate of new fosfamides in phase III studies in advanced soft tissue sarcoma. (2017) (10)
Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma (2018) (10)
The effectiveness of a nurse-led intervention with the distress thermometer for patients treated with curative intent for breast cancer: design of a randomized controlled trial (2016) (9)
LBA2 DeFi: A phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors (DT) (2022) (9)
The relation between soluble apoptotic proteins and subclinical cardiotoxicity in adjuvant-treated breast cancer patients. (2006) (9)
Incorporating the Patient Voice in Sarcoma Research: How Can We Assess Health-Related Quality of Life in This Heterogeneous Group of Patients? A Study Protocol (2020) (9)
A Timely Oral Option: Single‐Agent Vinorelbine in Desmoid Tumors (2020) (9)
Increased CHEK2 1100delC genotype frequency (also) in unselected breast cancer patients. (2004) (9)
High‐dose chemotherapy with stem cell reinfusion and growth factor support for solid tumors (1995) (9)
EORTC SPECTA‐AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe (2019) (9)
Age-related differences of oncological outcomes in primary extremity soft tissue sarcoma: a multistate model including 6260 patients. (2020) (9)
A randomized, double-blind, multicentre study comparing daily 2 and 5 mg of tropisetron for the control of nausea and vomiting induced by low-dose cisplatin- or non-cisplatin-containing chemotherapy. (1996) (8)
Health-Related Quality of Life in Patients With Sarcoma: Enhancing Personalized Medicine. (2018) (8)
IGF signaling pathway analysis of osteosarcomas reveals the prognostic value of pAKT localization. (2013) (8)
The patient perspective in the era of personalized medicine: What about scanxiety? (2021) (8)
Decision aids for second-line palliative chemotherapy: a randomised phase II multicentre trial (2017) (8)
Promising management of pazopanib-induced liver toxicity (2015) (8)
Early Metabolic Response as a Predictor of Treatment Outcome in Patients With Metastatic Soft Tissue Sarcomas (2019) (8)
Cetuximab reduces the accumulation of radiolabeled bevacizumab in cancer xenografts without decreasing VEGF expression. (2014) (8)
The Role of Local Therapy in Multi-focal Epithelioid Haemangioendothelioma (2019) (8)
Dose escalation of dacarbazine combined with interferon alpha-2a, G-CSF and ondansetron in patients with metastatic melanoma. (1994) (8)
Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database (2018) (8)
Caregivers of patients receiving long-term treatment with a tyrosine kinase inhibitor (TKI) for gastrointestinal stromal tumour (GIST): a cross-sectional assessment of their distress and burden* (2018) (8)
Genetic Variants as Predictive Markers for Ototoxicity and Nephrotoxicity in Patients with Locally Advanced Head and Neck Cancer Treated with Cisplatin-Containing Chemoradiotherapy (The PRONE Study) (2019) (8)
Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas. (2021) (8)
Liquid Biopsies in Sarcoma Clinical Practice: Where Do We Stand? (2021) (7)
Health-Related Quality of Life Issues in Adolescents and Young Adults with Cancer: Discrepancies with the Perceptions of Health Care Professionals (2021) (7)
The Perceived Impact of Length of the Diagnostic Pathway Is Associated with Health-Related Quality of Life of Sarcoma Survivors: Results from the Dutch Nationwide SURVSARC Study (2020) (7)
Treatment of advanced seminoma with cyclophosphamide, vincristine and carboplatin on an outpatient basis. (1996) (7)
5‐fluorouracil/leucovorin/interferon alpha‐2a in patients with advanced colorectal cancer. Effects of maintenance therapy on remission duration (1995) (7)
Teniposide for meningeal carcinomatosis of small cell lung cancer. (1993) (7)
Promises and challenges of positron emission tomography for assessment of sarcoma in daily clinical practice (2008) (7)
Surrogate endpoints in advanced sarcoma trials: a meta-analysis (2018) (7)
'This is not part of my life plan': A qualitative study on the psychosocial experiences and practical challenges in young adults with cancer age 25 to 39 years at diagnosis. (2021) (7)
Metastatic Soft Tissue Sarcomas in Adolescents and Young Adults: A Specialist Center Experience (2020) (7)
When hope is all there is left. (2011) (7)
Long-term results of induction- and intensification chemotherapy supported with autologous bone marrow reinfusion in patients with disseminated or T4 breast cancer. (1995) (7)
Lessons from an unusual case: malignancy associated hypercalcemia, pancreatitis and respiratory failure due to ARDS. (1999) (7)
Health-related quality Of Life In patients with advanced Soft TIssue sarcomas treated with Chemotherapy (The HOLISTIC study): protocol for an international observational cohort study (2020) (7)
Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials. (2018) (6)
Ataxia following docetaxel infusion. (1997) (6)
Olaratumab in soft-tissue sarcomas. (2016) (6)
Pulmonary function after high-dose chemotherapy with autologous bone marrow transplantation and radiotherapy in patients with advanced loco-regional breast cancer. (1997) (6)
1526MO GEMMK: A phase I study of gemcitabine (gem) and pembrolizumab (pem) in patients (pts) with leiomyosarcoma (LMS) and undifferentiated pleomorphic sarcoma UPS) (2021) (6)
Mitoxantrone: bluebeard for malignancies. (1990) (6)
Anthracyclines - Pharmacology and Resistance, A Review (1995) (6)
Surgical and medical management of small bowel gastrointestinal stromal tumors: A report of the Dutch GIST registry. (2019) (6)
Methotrexate plus or minus cetuximab as first‐line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib‐randomized phase II study Commence (2020) (6)
Health-related quality of life and symptom burden of epithelioid hemangioendothelioma patients: a global patient-driven Facebook study in a very rare malignancy (2020) (6)
Successful treatment on an out-patient basis of a patient with Down's syndrome and disseminated testicular seminoma. (1996) (6)
Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database study. (2018) (6)
Fatal heart failure in a young adult female sarcoma patient treated with pazopanib (2017) (6)
Chemotherapy for metastatic seminoma in elderly patients. (2003) (5)
Reply letter to: pitfalls and limitations of a single-centre, retrospectively derived prognostic score for phase I oncology trial participant - reply to Füssenich et al.: a new, simple and objective prognostic score for phase I cancer patients. (2012) (5)
Positron emission tomography response criteria in solid tumours criteria for quantitative analysis of [18F]-fluorodeoxyglucose positron emission tomography with integrated computed tomography for treatment response assessment in metastasised solid tumours: All that glitters is not gold. (2016) (5)
Syndrome X in testicular-cancer survivors. (2001) (5)
Assessing the Desmoid-Type Fibromatosis Patients' Voice: Comparison of Health-Related Quality of Life Experiences from Patients of Two Countries (2020) (5)
Neoadjuvant chemotherapy in localised soft-tissue sarcomas: where do we go from here? (2017) (5)
Willingness to accept chemotherapy and attitudes towards costs of cancer treatment; A multisite survey study in the Netherlands. (2016) (5)
The route to diagnosis of sarcoma patients: Results from an interview study in the Netherlands and the United Kingdom (2020) (5)
Redefining the standard of care in metastatic leiomyosarcoma. (2015) (5)
A 20-year-old male with thoracic pain and a lower thoracic mass (2005) (5)
Endoscopy in patients with diarrhea during treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors: Is the cause in the mucosa? (2016) (5)
Central venous access related adverse events after trabectedin infusions in soft tissue sarcoma patients; experience and management in a nationwide multi-center study (2017) (5)
High prevalence of late adverse events in malignant bone tumour survivors diagnosed at adult age. (2014) (5)
Systemic treatment of advanced clear cell sarcoma: results from a retrospective international series from the World Sarcoma Network (2022) (5)
PropAngio study protocol: a neoadjuvant trial on the efficacy of propranolol monotherapy in cutaneous angiosarcoma—a proof of principle study (2020) (5)
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'. (2019) (5)
High-dose methotrexate, vincristine and cisplatin as salvage treatment for relapsed non-seminomatous germ-cell cancer. (1995) (5)
Gynecological Sarcomas: Molecular Characteristics, Behavior, and Histology-Driven Therapy (2020) (5)
The Evaluation of Health-Related Quality of Life Issues Experienced by Patients with Desmoid-Type Fibromatosis (The QUALIFIED Study)—A Protocol for an International Cohort Study (2021) (5)
The impact of a 1‐hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure (2021) (5)
The age-related impact of surviving sarcoma on health-related quality of life: data from the SURVSARC study (2021) (5)
Informal caregiver well-being during and after patients’ treatment with adjuvant chemotherapy for colon cancer: a prospective, exploratory study (2020) (5)
Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments. (2022) (4)
Does a glass of Coke boost the exposure to imatinib in gastrointestinal stromal tumour patients after gastrectomy? (2017) (4)
The heterogeneity of Epithelioid Hemangioendothelioma (EHE): A case series and review of the literature with emphasis on treatment options. (2021) (4)
The role of perioperative chemotherapy in primary high-grade extremity soft tissue sarcoma: a risk-stratified analysis using PERSARC. (2022) (4)
The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease. (1995) (4)
Screening for infectious foci in breast cancer patients prior to high-dose chemotherapy and stem cell transplantation. (2003) (4)
Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC study (2021) (4)
Development of a Disease-Specific Health-Related Quality of Life Questionnaire (DTF-QoL) for Patients with Desmoid-Type Fibromatosis (2022) (4)
Radiolabeled imaging probes targeting angiogenesis for personalized medicine. (2014) (4)
Weight loss induced by tyrosine kinase inhibitors of the vascular endothelial growth factor pathway (2012) (4)
Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer. (2015) (4)
The early effect of sunitinib on insulin clearance in patients with metastatic renal cell carcinoma. (2016) (4)
Dying at the right time: a modern dilemma. (2009) (4)
Exploring the Routine Administration of Decision Aids for Palliative Chemotherapy to Patients by Nurses: A Qualitative Study Among Nurses and Oncologists (2015) (4)
Synovial Sarcoma of the Thyroid Gland, Diagnostic Pitfalls and Clinical Management (2018) (4)
Ototoxicity in locally advanced head and neck cancer patients treated with induction chemotherapy followed by intermediate or high‐dose cisplatin‐based chemoradiotherapy (2018) (4)
Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature (2022) (4)
1415OOUTCOME OF FIRST-LINE TREATMENT OF ELDERLY ADVANCED SOFT TISSUE SARCOMA (STS) PATIENTS: A POOLED ANALYSIS OF ELEVEN EORTC SOFT TISSUE AND BONE SARCOMA GROUP TRIALS. (2014) (4)
Genomic and transcriptomic characterization of desmoplastic small round cell tumors (2021) (4)
Quality of life of patients with locally advanced head and neck cancer treated with induction chemotherapy followed by cisplatin-containing chemoradiotherapy in the Dutch CONDOR study: a randomized controlled trial (2017) (4)
[Diagnosis and treatment of HIV-related Kaposi's sarcoma]. (2006) (4)
Scrotal and inguinal mass. (2010) (3)
Recruiting Adolescent and Young Adult Cancer Survivors for Patient-Reported Outcome Research: Experiences and Sample Characteristics of the SURVAYA Study (2022) (3)
Circulating apoptosis-related proteins in long-term disease free breast cancer survivors. (2004) (3)
Correlation between imatinib trough levels and clinical benefit in gastrointestinal stromal tumors (GIST): Results of a prospective population pharmacokinetic study. (2011) (3)
The effect of gastrectomy on regorafenib exposure and progression‐free survival in patients with advanced gastrointestinal stromal tumours (2019) (3)
Buruli ulcer in West Africa. (1990) (3)
18F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors (2012) (3)
Clinical Impact of Prospective Whole Genome Sequencing in Sarcoma Patients (2022) (3)
Health-related quality of life after isolated limb perfusion compared to extended resection, or amputation for locally advanced extremity sarcoma: Is a limb salvage strategy worth the effort? (2021) (3)
High dose oral amiodarone added to doxorubicin and vindesine for overcoming multidrug resistance in solid tumors. (1994) (3)
Biodistribution and pharmacokinetics of radiolabeled trastuzumab in HER2-positive metastatic breast cancer. (2004) (3)
Health-related quality of life of patients treated with chemoradiotherapy plus or minus prophylactic antibiotics to reduce the number of pneumonias for locally advanced head and neck cancer, the PANTAP study. (2019) (3)
Psychological aspects in patients with advanced cancer receiving lifelong systemic treatment: protocol for a scoping review (2021) (3)
Effective conditioning regimen for premenopausal patients with advanced breast cancer. (1994) (3)
Comprehensive Assessment of Incidence, Risk Factors, and Mechanisms of Impaired Medical and Psychosocial Health Outcomes among Adolescents and Young Adults with Cancer: Protocol of the Prospective Observational COMPRAYA Cohort Study (2021) (3)
[Buruli ulcer (Mycobacterium ulcerans infection); report from the International Congress in Yamoussoukro, Ivory Coast]. (1999) (3)
Beyond Teenage and Young Adult Cancer Care: Care Experiences of Patients Aged 25-39 Years Old in the UK National Health Service. (2021) (3)
Differences in Internet Use and eHealth Needs of Adolescent and Young Adult Versus Older Cancer Patients; Results from the PROFILES Registry (2021) (3)
Short- and long-term impact of cancer on employment and financial outcomes of adolescents and young adults (AYAs): a large population-based case-control registry study in the Netherlands (2022) (2)
Quality of life and experiences of sarcoma trajectories (the QUEST study): protocol for an international observational cohort study on diagnostic pathways of sarcoma patients (2020) (2)
The effect of surgery in tenosynovial giant cell tumours as measured by patient‐reported outcomes on quality of life and joint function (2019) (2)
Psychosocial Aspects of Living Long Term with Advanced Cancer and Ongoing Systemic Treatment: A Scoping Review (2022) (2)
[Imatinib, a specific tyrosine-kinase inhibitor, for the treatment of patients with a gastrointestinal stroma cell tumor]. (2003) (2)
Symptoms reported by gastrointestinal stromal tumour (GIST) patients on imatinib treatment: combining questionnaire and forum data (2022) (2)
New benchmarks to design clinical trials with advanced or metastatic liposarcoma or synovial sarcoma patients: An EORTC - Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for soft-tissue sarcomas. (2022) (2)
Local control and postponement of systemic therapy after modest dose radiotherapy in oligometastatic myxoid liposarcomas. (2021) (2)
‘I thought I had fibroids, and now I don’t’: a mixed method study on health-related quality of life in uterine sarcoma patients (2022) (2)
How to diagnose cardiac tamponade. (2002) (2)
FDG-PET/CT in a Patient with Poor-Risk Non-Seminoma Testis with Mature Teratoma and Secondary Gliosarcoma: Multimodality Imaging for Guiding Multimodality Treatment (2015) (2)
In vitro and in vivo studies on the action of BW502U83, an arylmethylaminopropanediol (1995) (2)
Identifying health-related quality of life cut-off scores that indicate the need for supportive care in young adults with cancer (2022) (2)
Unraveling Desmoid-Type Fibromatosis-Specific Health-Related Quality of Life: Who Is at Risk for Poor Outcomes (2022) (2)
Setting the international research agenda for sarcoma together with patients and carers: first results of the Sarcoma Patient EuroNet (SPAEN) priority setting partnership (2022) (2)
Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors. (2023) (2)
Biology-Guided Precision Medicine in Rare Cancers: Lessons from Sarcomas and Neuroendocrine Tumours. (2022) (2)
Describing Unmet Supportive Care Needs among Young Adults with Cancer (25–39 Years) and the Relationship with Health-Related Quality of Life, Psychological Distress, and Illness Cognitions (2021) (2)
Controversies in the management of patients with soft tissue sarcoma: Recommendations of the Conference on State of Science in Sarcoma 2022. (2022) (1)
First‐line chemotherapy in advanced intra‐abdominal well‐differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis (2022) (1)
Clustering of EORTC QLQ-C30 health-related quality of life scales across several cancer types: Validation study. (2022) (1)
Desmoid-type fibromatosis: toward a holistic management (2021) (1)
Targeting the FAK-Src Complex in Desmoplastic Small Round Cell Tumors, Ewing Sarcoma, and Rhabdomyosarcoma (2022) (1)
Clinical Trials for Real-World Elderly Patients With Metastatic Soft-Tissue Sarcomas: The Importance of Study Design and Patient-Reported Outcomes. (2021) (1)
A qualitative study on the challenges health care professionals face when caring for adolescents and young adults with an uncertain and/or poor cancer prognosis (2022) (1)
Time to target evaluation criteria of targeted therapies. (2009) (1)
Targeted therapy for Ewing's sarcoma: significance of heterogeneity. (2010) (1)
Heritable defects in telomere and mitotic function selectively predispose to sarcomas (2023) (1)
Heritable defects in telomere and mitotic function selectively predispose to sarcomas (2023) (1)
Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients (2019) (1)
Supportive care needs of patients living with an extremely rare and unpredictable cancer: The Epithelioid Haemangioendothelioma patient experience. (2021) (1)
Young adults: a unique group in cancer epidemiological research. (2018) (1)
[Diarrhoea and fever in chemotherapy patients due to listeriosis]. (2010) (1)
[89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma (2022) (1)
Sex differences in patients with gastrointestinal stromal tumours: do they exist and does it affect survival? (2022) (1)
Dacarbazine DTIC and carboplatin as an outpatient treatment for disseminated malignant melanoma. (2001) (1)
How did partners experience cancer patients' participation in a phase I study? An observational study after a patient's death (2015) (1)
Health-Related Quality of Life Issues Experienced by Thoracic and Breast Sarcoma Patients: A Rare and Understudied Group (2021) (1)
“Finding my way in a maze while the clock is ticking”: The daily life challenges of adolescents and young adults with an uncertain or poor cancer prognosis (2022) (1)
A Sarcoid-like Reaction in a Patient with Hemangiopericytoma Mediastinal lymphadenopathy resulting in Confusion about Therapy (2003) (1)
PARP inhibition in UV-associated angiosarcoma preclinical models (2021) (1)
Prognosis of Patients with Cutaneous Angiosarcoma After Surgical Resection with Curative Intent: Is There a Difference Between the Subtypes? (2022) (1)
Different effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple-negative invasive ductal breast carcinoma. (2009) (1)
[Providing information about metastasised cancer could be better: time for a good talk]. (2013) (0)
Comprehensive molecular profiling of sarcomas in adolescent and young adult patients: Results of the EORTC SPECTA-AYA international proof-of-concept study. (2022) (0)
Learning from long-term adolescent and young adult (AYA) cancer survivors regarding their age-specific care needs to improve current AYA care programs. (2023) (0)
Progressive dysphagia. (1991) (0)
[2 patients with brain metastases who became pregnant during phenytoin administration]. (1992) (0)
Impaired social functioning in adolescent and young adult sarcoma survivors: Prevalence and risk factors (2023) (0)
Genome-wide analyses of platinum-induced ototoxicity in childhood cancer patients: Results of GO-CAT and United Kingdom MAGIC consortia (2023) (0)
Health-related quality of life priorities in adolescents and young adults (AYA) with cancer: Discrepancies with health care professionals' perceptions. (2018) (0)
FELD better not thinking of metastases only when liver lesions appear after bleomycin-based treatment for non-seminoma testis from metastases (2013) (0)
Anaplastic lymphoma kinase (ALK) in rhabdomyosarcoma. (2011) (0)
1526TiP TOLERANCE: An EORTC STBSG-QLG-ETF 3-arm randomized study on health-related quality of life of elderly patients with advanced soft tissue sarcoma undergoing doxorubicin alone three weekly or doxorubicin weekly or cyclophosphamide plus predniso(lo)ne treatment (2022) (0)
1456PTHE ROLE OF AXL IN EWING SARCOMA. (2014) (0)
Pregnancy-associated desmoid fibromatosis: A Dutch multi-centre retrospective study. (2022) (0)
Age-related sarcoma patient experience: results from a national survey in England (2018) (0)
The effectiveness of a nurse-led intervention with the distress thermometer for patients treated with curative intent for breast cancer: design of a randomized controlled trial (2016) (0)
Bone sarcoma during pregnancy: an example of personalized multidisciplinary care (2018) (0)
1345PCAREGIVERS' BURDEN AND FATIGUE DURING PATIENTS' (PTS) TREATMENT WITH CURATIVE, CONCOMITANT CHEMORADIOTHERAPY (CRT) FOR LOCALLY ADVANCED HEAD AND NECK CANCER (LAHNC): A PROSPECTIVE, OBSERVATIONAL STUDY. (2014) (0)
Gemcitabine Re-challenge in Metastatic Soft Tissue Sarcomas: A Therapeutic Option for Selected Patients (2019) (0)
Sequential (ST) versus combination (CT) chemotherapy in older patients (pts) with advanced colorectal cancer (aCRC): A retrospective analysis of the CAIRO study. (2016) (0)
Sample Bias in Web-Based Patient-Generated Health Data of Dutch Patients With Gastrointestinal Stromal Tumor: Survey Study (2022) (0)
Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness (2018) (0)
No association between the Arg201Gly polymorphism of the DCC gene and colorectal cancer. (2004) (0)
ASO Visual Abstract: Prognosis of Patients with Cutaneous Angiosarcoma After Surgical Resection with Curative Intent—Is There a Difference Between the Subtypes? (2022) (0)
Prognostic Significance of Bone Metastasis in Soft Tissue Sarcoma Patients Receiving Palliative Systemic Therapy: An Explorative, Retrospective Pooled Analysis of the EORTC-Soft Tissue and Bone Sarcoma Group (STBSG) Database (2022) (0)
Physical symptom burden in patients with desmoid-type fibromatosis and its impact on health-related quality of life and healthcare use. (2023) (0)
An unusual presentation of sepsis caused by coagulase-negative staphylococci. (1999) (0)
1433PBURDEN AND DISTRESS OF CAREGIVERS OF PATIENTS (PTS) ON TYROSINE KINASE INHIBITORS (TKI) FOR GASTROINTESTINAL STROMAL TUMORS (GIST): A CROSS-SECTIONAL STUDY. (2014) (0)
131TiP Measuring health-related quality of life in solid rare cancer patients: A study protocol (2023) (0)
The Prolonged Diagnostic Pathway of Young Adults (Aged 25–39) with Cancer in the United Kingdom: Results from the Young Adult Cancer Patient Journey Study (2021) (0)
Age as prognostic factor in osteosarcoma. (2009) (0)
Next Step for Global Adolescent and Young Adult Oncology: A Core Patient-Centered Outcome Set. (2021) (0)
Myocardial HER2 expression with 111In-DTPA-trastuzmab scan in patients shortly after anthracycline treatment. (2006) (0)
Clinical trials in desmoid‐type fibromatosis in children and adults: A systematic review (2022) (0)
PALETTE: A randomized, double-blind phase III trial of pazopanib versus placebo in patients with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy-An EORTC STBSG Global Network Study (EORTC 62072). (2011) (0)
Corrigendum to "Local control and postponement of systemic therapy after modest dose radiotherapy in oligometastatic myxoid liposarcomas" [Radiother. Oncol. 158 (2021) 33-39]. (2021) (0)
A successful approach to overcome imatinib-induced skin toxicity in a GIST patient (2016) (0)
Fertility related concerns In male Adolescent and Young Adult (AYA) cancer survivors from a multicenter cohort study (SURVAYA) (2023) (0)
Psychosocial consequences of surviving cancer diagnosed and treated in childhood versus in adolescence/young adulthood: A call for clearer delineation between groups (2022) (0)
1515PCHANGES IN INSULIN CLEARANCE DURING SUNITINIB TREATMENT. (2014) (0)
EORTC is 60 - and far from contemplating retirement. (2022) (0)
Lesion detection by ceCT, 89Zr-girentuximab and FDG PET/CT in newly diagnosed patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC). (2018) (0)
Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma (2023) (0)
FDG-PET as a predicitve marker for primary resistance to imatinib (IM) in patients with gastrointestinal stromal tumors (GIST). (2011) (0)
1410PADOLESCENT AND YOUNG ADULT CANCER PATIENT (AYAS) PARTICIPATION AS DRIVER OF A NEW "AYA PROOF" CANCER CARE CONCEPT. (2014) (0)
Malignant transformation in an area with elevated F-18 FDG uptake within a low metabolic benign neurofibroma. (2010) (0)
[Determination of blood levels for oral anticancer drugs]. (2014) (0)
[Care for adolescents and young adults with cancer; the role of a national platform]. (2019) (0)
Shedding a Light on the Challenges of Adolescents and Young Adults with Rhabdomyosarcoma (2022) (0)
AYAs' online information and eHealth needs: A comparison with healthcare professionals' perceptions (2022) (0)
“Double awareness”—adolescents and young adults coping with an uncertain or poor cancer prognosis: A qualitative study (2022) (0)
60P The diagnostic pathway of sarcoma patients: Results from the QUEST study in the Netherlands and the United Kingdom: A cohort study (2023) (0)
SLC7A8 coding for LAT2 is associated with early disease progression in osteosarcoma and transports doxorubicin (2022) (0)
Elevation of serum human chorionic gonadotrophin as the only indication for isolated cerebral relapse of a germ cell tumour of the testis. (1995) (0)
A young female with an endodermal sinus tumor in a pericardial localized cyst. (2000) (0)
Patients’ Preferences for Information About the Benefits and Risks of Second-Line Palliative Chemotherapy and Their Oncologist’s Awareness of These Preferences (2015) (0)
Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness (2018) (0)
[Expected survival with and without second-line palliative chemotherapy: who wants to know?]. (2015) (0)
Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer. (2023) (0)
Correlation of radiological and histopathological response after neoadjuvant radiotherapy in soft tissue sarcoma (2022) (0)
Abstract 2005: First results of the EORTC-SPECTA project on comprehensive molecular profiling of adolescent and young adult sarcoma patients (2022) (0)
Elevated preoperative serum interleukin-6 level is predictive for worse postoperative outcome after soft tissue sarcoma surgery (2023) (0)
A Negative Body Image among Adolescent and Young Adult (AYA) Cancer Survivors: Results from the Population-Based SURVAYA Study (2022) (0)
1491MO New benchmarks for designing clinical trials in advanced or metastatic liposarcoma (LPS) or synovial sarcoma (SS): An EORTC soft tissue and bone sarcoma group meta-analysis (2022) (0)
FELD better not thinking of metastases only when liver lesions appear after bleomycin-based treatment for non-seminoma testis from metastases (2013) (0)
Desmoid is not a sarcoma; reply to Sachdev et al. (2023) (0)
Fear of Cancer Recurrence in Sarcoma Survivors: Results from the SURVSARC Study (2022) (0)
Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness (2018) (0)
The patient's perspective on side effects of tyrosine kinase inhibitors in the treatment of advanced and metastatic gastrointestinal stromal tumors. (2023) (0)
Cetuximab in combination with methotrexate (MTX) as first-line treatment in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): A phase Ib randomized phase II study versus single agent MTX. (2018) (0)
A female with a leiomyosarcoma presenting with acute thoracic pain and dyspnoea. (2012) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Winette T. A. Van Der Graaf?

Winette T. A. Van Der Graaf is affiliated with the following schools:

Institute of Cancer Research
Seoul National University